• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Legislation Proposed to Curb Research Drug Costs, Improve Trial Transparency

Legislation Proposed to Curb Research Drug Costs, Improve Trial Transparency

April 18, 2022

Two new bicameral bills introduced in Congress would seek to rein in research spending by forcing drugmakers to disclose their clinical trial costs and sell certain drugs/biologics at the manufacturer’s cost when they’re used in clinical trials. They will next be discussed in committee or subcommittee meetings.

The Pharmaceutical Research and Transparency Act of 2022, introduced by Rep. Carolyn Maloney (D-N.Y.) and Sens. Debbie Stabenow (D-Mich.) and Tina Smith (D-Minn.), is aimed at addressing a lack of transparency around the costs drug companies incur for clinical trials.

Specifically, the bill would establish a public database and require companies to submit cost data to it within a year of a trial’s conclusion. In addition, the legislation would charge drugmakers with sharing their trial costs in yearly securities filings.

The Discounted Drugs for Clinical Trials Act, introduced by the same people, would allow researchers to purchase expensive drugs and biologics at a price no greater than what they cost to manufacture as long as the products are being used in research.

Read the Pharmaceutical Research and Transparency Act of 2022 bill here: https://bit.ly/3jzbUzX.

Read the Discounted Drugs for Clinical Trials Act here: https://bit.ly/38IlJcV.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing